Community Translations
Community Translations
Abemaciclib becomes first CDK inhibitor to clinch single-agent approval for breast cancer
Community Translations
Checkpoint inhibitors forge new treatment paradigm for metastatic bladder cancer
Community Translations
Pembrolizumab for dMMR/MSI-H tumors marks first tumor agnostic FDA approval
Community Translations
Brigatinib approval yields additional treatment options for crizotinib-resistant, ALK-positive NSCLC patients
Community Translations
PD-L1-targeting drug atezolizumab nabs approval for non-small cell lung cancer
Community Translations
Ribociclib: another CDK inhibitor hits the mark in breast cancer
Community Translations
Approval makes olaratumab the first first-line treatment option for soft tissue sarcoma in more than 40 years
Community Translations
Rucaparib – second PARP inhibitor hits the market for ovarian cancer
Community Translations
Lenvatinib expands its reach into renal cell carcinoma
The US Food and Drug Administration (FDA) expanded the approval of the multitargeted tyrosine kinase inhibitor lenvatinib to a second indication...